The Indus Hospital (TIH) — one of the five sites in Pakistan selected for the multi-country phase-III clinical trial of a potential Covid-19 vaccine — has seen a positive public response to the recent low-key launch of the trial, raising the hope that the effort would meet its target.
Till Saturday — day 18 of the trial — over 500 people volunteered for the research supported by CanSinoBio, a Chinese company which has developed the single dose adenovirus type-5 (Ad5)-vectored Covid-19 vaccine in collaboration with the Beijing Institute of Biotechnology.
According to researchers at TIH, the specific vaccine has already established its safety and efficacy in the previous trials held in China with no serious adverse effects.
According to the researchers, only healthy/stable people, aged 18 or older with no uncontrolled illness or disorder or history of lab-proven Covid-19, are inducted into the trial that will last for two months.
Read more here.
